{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:20:59Z","timestamp":1792113659963,"version":"4.4.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2025.101074","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T16:30:23Z","timestamp":1766161823000},"page":"101074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Hematologic malignancies and an overview of emerging therapies for hematologic malignancies: a systematic review"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6077-3123","authenticated-orcid":false,"given":"Kazem","family":"Ghaffari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4769-3847","authenticated-orcid":false,"given":"Amin","family":"Moradi Hasan-Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-7471","authenticated-orcid":false,"given":"Masoud","family":"Etedali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-0822","authenticated-orcid":false,"given":"Shaban","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4996-7656","authenticated-orcid":false,"given":"Ali","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0001","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12940-020-00582-1","article-title":"A systematic review and meta-analysis of haematological malignancies in residents living near petrochemical facilities","volume":"19","author":"Jephcote","year":"2020","journal-title":"Environ. Health"},{"issue":"25","key":"10.1016\/j.ctarc.2025.101074_bib0002","first-page":"2881","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/healthcare13050467","article-title":"The effect of exercise-based interventions on health-related quality of life of patients with hematological malignancies: a systematic review and meta-analysis","author":"Borsati","year":"2025","journal-title":"Healthcare"},{"issue":"5","key":"10.1016\/j.ctarc.2025.101074_bib0004","first-page":"515","article-title":"Frailty and the management of hematologic malignancies","volume":"131","author":"Abel","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1263834","article-title":"Application of cell-derived exosomes in the hematological malignancies therapy","volume":"14","author":"Ghaffari","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.ctarc.2025.101074_bib0006","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1200\/JCO.18.02386","article-title":"Palliative and end-of-life care for patients with hematologic malignancies","volume":"38","author":"El-Jawahri","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172641","article-title":"Hematological malignancies and molecular targeting therapy","volume":"862","author":"Shimada","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0008","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","author":"Anand","year":"2022","journal-title":"Genes Dis."},{"key":"10.1016\/j.ctarc.2025.101074_bib0009","unstructured":"DeVita V.T., Hellman S., Rosenberg S.A. Cancer, principles and practice of oncology. (No Title). 2001."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101074_bib0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"5405","key":"10.1016\/j.ctarc.2025.101074_bib0011","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"9464","key":"10.1016\/j.ctarc.2025.101074_bib0012","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101074_bib0013","first-page":"1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0014","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jmv.25423","article-title":"Human platelet antigens polymorphisms; association to the development of liver fibrosis in patients with chronic hepatitis C","volume":"92","author":"Ghasemi","year":"2020","journal-title":"J. Med. Virol."},{"issue":"14","key":"10.1016\/j.ctarc.2025.101074_bib0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2025.101074_bib0016","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2025.101074_bib0017","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101074_bib0018","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0019","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ctarc.2025.101074_bib0020","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ctarc.2025.101074_bib0021","first-page":"2391","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"11","key":"10.1016\/j.ctarc.2025.101074_bib0022","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.hlc.2020.04.019","article-title":"Supportive care interventions to promote health-related quality of life in patients living with heart failure: a systematic review and meta-analysis","volume":"29","author":"Kyriakou","year":"2020","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.ctarc.2025.101074_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-021-00198-2","article-title":"A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990\u20132017","volume":"10","author":"Keykhaei","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101074_bib0024","first-page":"397","article-title":"Leukemia: a review article","volume":"1","author":"Manisha","year":"2012","journal-title":"Int. J. Adv. Res. Pharm. Bio Sci."},{"key":"10.1016\/j.ctarc.2025.101074_bib0025","doi-asserted-by":"crossref","DOI":"10.4103\/abr.abr_103_21","article-title":"A retrospective cytogenetic abnormality in pediatric acute lymphoblastic leukemia: report of 11 years","volume":"11","author":"Ghaffari","year":"2022","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.ctarc.2025.101074_bib0026","doi-asserted-by":"crossref","DOI":"10.4103\/abr.abr_157_21","article-title":"Evaluation of blood pressure in pediatric survivors of acute lymphoblastic leukemia and healthy children; A case-control study","volume":"11","author":"Ghaffari","year":"2022","journal-title":"Adv. Biomed. Res."},{"issue":"5","key":"10.1016\/j.ctarc.2025.101074_bib0027","first-page":"213","article-title":"Methylation status of SOX17 and RUNX3 genes in acute leukemia","volume":"7","author":"Ghasemi","year":"2015","journal-title":"Iran. J. Blood Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0028","first-page":"1","article-title":"Comparison of secreted frizzled-related protein-4 &-5 promoter methylation in patients with acute myeloblastic leukemia and healthy individuals","volume":"13","author":"Ghaffari","year":"2021","journal-title":"Iran. J. Blood Cancer"},{"key":"10.1016\/j.ctarc.2025.101074_bib0029","doi-asserted-by":"crossref","unstructured":"Ghasemi A., Ghotaslou A., Mohammadi M., Abbasian S., Ghaffari K. Methylation of the Wnt signaling antagonist, Wnt inhibitory factor 1 and Dickkopf-1 genes in acute myeloid leukemia at the time of diagnosis. 2016.","DOI":"10.17795\/zjrms-5874"},{"key":"10.1016\/j.ctarc.2025.101074_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1295816","article-title":"Effect of oral silymarin on liver function in pediatric acute lymphoblastic leukemia in the maintenance phase: a double-blind randomized clinical trial","volume":"15","author":"Eghbali","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101074_bib0031","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PPO.0000000000000451","article-title":"Lymphoma classification","volume":"26","author":"de Leval","year":"2020","journal-title":"Cancer J."},{"issue":"5","key":"10.1016\/j.ctarc.2025.101074_bib0032","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ctarc.2025.101074_bib0033","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: a review","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01116-z","article-title":"Molecular pathogenesis of the myeloproliferative neoplasms","volume":"14","author":"Greenfield","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101074_bib0036","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41375-023-01852-w","article-title":"Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment","volume":"37","author":"Hemminki","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2025.101074_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1360075","article-title":"The effect of vitamin D deficiency on platelet parameters in patients with COVID-19","volume":"14","author":"Talebzadeh","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101074_bib0038","first-page":"147","article-title":"Evaluation of minimal residual disease in acute myeloid leukemia with NPM1 marker","volume":"10","author":"Ghandforoush","year":"2016","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101074_bib0039","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/joim.13395","article-title":"Advances in immune therapies in hematological malignancies","volume":"292","author":"Mazzarella","year":"2022","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101074_bib0040","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11864-023-01049-4","article-title":"Small-molecule compounds boost CAR-T cell therapy in hematological malignancies","volume":"24","author":"Cao","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2025.101074_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27073","article-title":"NHL in adolescents and young adults: a unique population","volume":"65","author":"Hochberg","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ctarc.2025.101074_bib0042","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1007\/s12325-020-01314-0","article-title":"The myeloproliferative neoplasm landscape: a patient\u2019s eye view","volume":"37","author":"Petruk","year":"2020","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101074_bib0043","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/ijo.2018.4661","article-title":"From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment","volume":"54","author":"Schirrmacher","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0044","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.htct.2022.02.004","article-title":"Evaluating aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: a triple-blinded randomized clinical trial","volume":"45","author":"Eghbali","year":"2023","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"10.1016\/j.ctarc.2025.101074_bib0045","doi-asserted-by":"crossref","DOI":"10.18502\/ijpho.v12i1.8355","article-title":"Dwindled serum IgG levels of Rubella, Diphtheria toxin, Hepatitis B virus and Tetanus Toxoid after chemotherapy; a report from Iranian children with malignancy","author":"Ghaffari","year":"2022","journal-title":"Iran. J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0046","article-title":"Magnesium supplementation may not be protective against carboplatin-induced nephrotoxicity but may be beneficial for children suffering malignancies: a randomized clinical trial","volume":"12","author":"Hadadhania","year":"2023","journal-title":"Adv. Biomed. Res."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101074_bib0047","first-page":"289","article-title":"Chemotherapy and beyond: infections in the era of old and new treatments for hematologic malignancies","volume":"33","author":"Atkins","year":"2019","journal-title":"Infect. Dis. Clin."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0048","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4103\/abr.abr_356_22","article-title":"The effect and safety of olanzapine on nausea and vomiting in children receiving moderately emetogenic chemotherapy","volume":"12","author":"Eghbali","year":"2023","journal-title":"Adv. Biomed. Res."},{"issue":"6","key":"10.1016\/j.ctarc.2025.101074_bib0049","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/jcm10061169","article-title":"Challenges and advances in managing thrombocytopenic cancer patients","volume":"10","author":"Leader","year":"2021","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2025.101074_bib0050","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30328","article-title":"The effects of LactoCare synbiotic administration on chemotherapy-induced nausea, vomiting, diarrhea, and constipation in children with ALL: a double-blind randomized clinical trial","volume":"70","author":"Eghbali","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2025.101074_bib0051","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1066748","article-title":"Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: a single center study","volume":"13","author":"Lu","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.ctarc.2025.101074_bib0053","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3109\/10428194.2016.1167204","article-title":"Advances in haploidentical stem cell transplantation for hematologic malignancies","volume":"57","author":"Montoro","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.ctarc.2025.101074_bib0054","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101074_bib0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11899-023-00694-8","article-title":"Managing survivorship after hematopoietic cell transplantation","volume":"18","author":"Khera","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.ctarc.2025.101074_bib0056","series-title":"Radiation Therapy in Hematologic Malignancies: An Illustrated Practical Guide","author":"Dabaja","year":"2017"},{"key":"10.1016\/j.ctarc.2025.101074_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1205836","article-title":"Radiation for hematologic malignancies: from cell killing to immune cell priming","volume":"13","author":"Dabaja","year":"2023","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2025.101074_bib0058","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3390\/antiox9111116","article-title":"Radioprotective agents and enhancers factors. Preventive and therapeutic strategies for oxidative induced radiotherapy damages in hematological malignancies","volume":"9","author":"Allegra","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.ctarc.2025.101074_bib0059","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-319-76457-3_18","article-title":"Evidence-based nursing of patients with hematologic malignancies","author":"Crombez","year":"2019","journal-title":"Princ. Nurs. Oncol. New Chall."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","article-title":"Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101074_bib0061","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ctarc.2025.101074_bib0062","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/CCO.0000000000000871","article-title":"Current status of phosphoinotiside-3 kinase inhibitors in blood cancers","volume":"34","author":"Shouse","year":"2022","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0063","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-022-01328-x","article-title":"Targeting macrophages in hematological malignancies: recent advances and future directions","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0064","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2077898","article-title":"Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy","volume":"11","author":"Petrazzuolo","year":"2022","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101074_bib0065","first-page":"184","article-title":"Analysis of expression of SIRT1 gene in patients with chronic myeloid leukemia resistant to imatinib mesylate","volume":"7","author":"Abbasian","year":"2015","journal-title":"Iran. J. Blood Cancer"},{"key":"10.1016\/j.ctarc.2025.101074_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.742802","article-title":"A review on the therapeutic role of TKIs in case of CML in combination with epigenetic drugs","volume":"12","author":"Amir","year":"2021","journal-title":"Front. Genet."},{"issue":"Supplement 1","key":"10.1016\/j.ctarc.2025.101074_bib0067","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1182\/blood-2022-156487","article-title":"Comedication of proton pump inhibitors and dasatinib is common in CML but XS004, a novel amorphous solid dispersion formulation of dasatinib, provides improved uptake and low pH-dependency, minimizing unwanted drug-drug interactions","volume":"140","author":"Larfors","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2025.101074_bib0068","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/S2152-2650(22)01357-X","article-title":"CML-030 do patients with CML-CP in MMR still have a hope to receive Nilotinib (Tasigna) while fasting during Ramadan? An unanswered question","volume":"22","author":"Maher","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ctarc.2025.101074_bib0069","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1182\/blood-2023-174324","article-title":"The real-world outcomes of Ponatinib in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan","volume":"142","author":"Takahashi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2025.101074_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101074_bib0071","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4103\/0973-1482.91999","article-title":"Monoclonal antibodies in hematological malignancies: past, present and future","volume":"7","author":"Tazi","year":"2011","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.ctarc.2025.101074_bib0072","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3389\/fimmu.2017.01936","article-title":"Monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets","volume":"8","author":"Cuesta-Mateos","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101074_bib0073","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.beha.2010.07.001","article-title":"Monoclonal antibodies in the treatment of hematologic malignancy","volume":"23","author":"Ball","year":"2010","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"18","key":"10.1016\/j.ctarc.2025.101074_bib0074","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of therapeutic antitumor monoclonal antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101074_bib0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101074_bib0076","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.3390\/ijms24032645","article-title":"Recent advances in the applications of small molecules in the treatment of multiple myeloma","volume":"24","author":"Abramson","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0077","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10229","key":"10.1016\/j.ctarc.2025.101074_bib0078","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101074_bib0079","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1002\/mco2.181","article-title":"Small molecule inhibitors targeting the cancers","volume":"3","author":"Liu","year":"2022","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.ctarc.2025.101074_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00901-6","article-title":"Emerging agents that target signaling pathways in cancer stem cells","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.ctarc.2025.101074_bib0081","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2217\/imt-2021-0065","article-title":"Immunotherapy in hematological malignancies: recent advances and open questions","volume":"13","author":"Tawfik","year":"2021","journal-title":"Immunotherapy"},{"issue":"17","key":"10.1016\/j.ctarc.2025.101074_bib0082","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune checkpoint inhibitors: basics and challenges","volume":"26","author":"Li","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.ctarc.2025.101074_bib0083","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101074_bib0084","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hon.2743","article-title":"Hematological toxicities in immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019","volume":"38","author":"Ye","year":"2020","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"22","key":"10.1016\/j.ctarc.2025.101074_bib0086","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.3390\/cancers15225399","article-title":"Clinical PD-1\/PD-L1 blockades in combination therapies for lymphomas","volume":"15","author":"Katsuya","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ctarc.2025.101074_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153114","article-title":"Immune checkpoint inhibitors in multiple myeloma: a review of the literature","volume":"216","author":"Caserta","year":"2020","journal-title":"Pathol. Res. Pract."},{"issue":"12","key":"10.1016\/j.ctarc.2025.101074_bib0088","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000802","article-title":"Chimeric antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: a scoping review","volume":"6","author":"Efficace","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.ctarc.2025.101074_bib0089","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.797440","article-title":"Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions","volume":"10","author":"Alnefaie","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0090","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies","author":"Abbasi","year":"2023","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101074_bib0091","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/ijp.ijp_531_20","article-title":"Chimeric antigen receptor T cell: a cancer immunotherapy","volume":"54","author":"Singh","year":"2022","journal-title":"Indian J. Pharmacol."},{"issue":"6","key":"10.1016\/j.ctarc.2025.101074_bib0092","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/d41573-022-00040-2","article-title":"Bispecific antibodies in oncology","volume":"21","author":"Esfandiari","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ctarc.2025.101074_bib0093","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pharmthera.2017.12.002","article-title":"Bispecific antibodies for cancer therapy: a review","volume":"185","author":"Krishnamurthy","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ctarc.2025.101074_bib0094","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.20.01564","article-title":"Immunotherapy of acute lymphoblastic leukemia and lymphoma with T cell-redirected bispecific antibodies","volume":"39","author":"Lussana","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1237738","article-title":"Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations","volume":"14","author":"Rubinstein","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0096","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5210459","article-title":"Genetically modified T-cell-based adoptive immunotherapy in hematological malignancies","volume":"2017","author":"Ye","year":"2017","journal-title":"J. Immunol. Res."},{"issue":"6230","key":"10.1016\/j.ctarc.2025.101074_bib0097","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2025.101074_bib0098","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101074_bib0099","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","article-title":"Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future","volume":"29","author":"Betof Warner","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ctarc.2025.101074_bib0100","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.3390\/cancers14123005","article-title":"Human \u03b3\u03b4 T cell subsets and their clinical applications for cancer immunotherapy","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0101","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4103\/jehp.jehp_1764_21","article-title":"Comparison of the effect of ferrous sulfate and ferrous gluconate on prophylaxis of iron deficiency in toddlers 6-24 months old: a randomized clinical trial","volume":"11","author":"Falahati","year":"2022","journal-title":"J. Educ. Health Promot."},{"issue":"11","key":"10.1016\/j.ctarc.2025.101074_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105326","article-title":"Immunotherapy approaches for hematological cancers","volume":"25","author":"Lanier","year":"2022","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0103","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"21","key":"10.1016\/j.ctarc.2025.101074_bib0104","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.3390\/ijms21218000","article-title":"Immunotherapy in hematologic malignancies: emerging therapies and novel approaches","volume":"21","author":"Noh","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101074_bib0105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003499","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types","volume":"9","author":"Kverneland","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2025.101074_bib0106","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1284326","article-title":"The effects of curcumin on hepatic T2* MRI and liver enzymes in patients with \u03b2-thalassemia major: a double-blind randomized controlled clinical trial","volume":"14","author":"Eghbali","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101074_bib0107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006193","article-title":"Epigenetics in cancer: a hematological perspective","volume":"12","author":"Stahl","year":"2016","journal-title":"PLoS Genet."},{"issue":"11","key":"10.1016\/j.ctarc.2025.101074_bib0108","article-title":"Advances in epigenetic cancer therapeutics","volume":"12","author":"Hillyar","year":"2020","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101074_bib0109","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3892\/or.2015.4100","article-title":"Nanotechnology applications in hematological malignancies","volume":"34","author":"Samir","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ctarc.2025.101074_bib0110","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/B978-0-12-823971-1.00019-2","article-title":"Applications of nanotechnology in biological systems and medicine","author":"Zain","year":"2022","journal-title":"Nanotechnol. Hematol. Blood Transfus. Artif. Blood"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0111","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101074_bib0112","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/joim.13697","article-title":"Novel precision medicine approaches and treatment strategies in hematological malignancies","volume":"294","author":"Rosenquist","year":"2023","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101074_bib0113","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000536","article-title":"Precision medicine in hematology 2021: definitions, tools, perspectives, and open questions","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.ctarc.2025.101074_bib0114","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ijc.34243","article-title":"Therapy resistance mechanisms in hematological malignancies","volume":"152","author":"Hofmann","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2025.101074_bib0115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41582-021-00461-4","article-title":"Identification of clinically relevant biomarkers of epileptogenesis\u2013a strategic roadmap","volume":"17","author":"Simonato","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ctarc.2025.101074_bib0116","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10565-016-9367-4","article-title":"Addressing heterogeneity of individual blood cancers: the need for single cell analysis","volume":"33","author":"Chu","year":"2017","journal-title":"Cell Biol. Toxicol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101074_bib0117","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001754","article-title":"Strategies for improving the management of immune-related adverse events","volume":"8","author":"Naing","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.ctarc.2025.101074_bib0118","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/tbm\/ibab091","article-title":"Financial toxicity in cancer care: origins, impact, and solutions","volume":"11","author":"Abrams","year":"2021","journal-title":"Transl. Behav. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101074_bib0119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225002102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225002102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:51:56Z","timestamp":1770655916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225002102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":119,"alternative-id":["S2468294225002102"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101074","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematologic malignancies and an overview of emerging therapies for hematologic malignancies: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101074"}}